Drugs for Relapse Prevention of Alcoholism
(Sprache: Englisch)
Alcoholism is a pathological behavioural syndrome, characterised by comp- sive alcohol use, craving and relapses, even recurring after many years of abstinence. It is suggested that chronic alcohol abuse leads to persistent changes within several...
Leider schon ausverkauft
versandkostenfrei
Buch (Gebunden)
203.29 €
Produktdetails
Produktinformationen zu „Drugs for Relapse Prevention of Alcoholism “
Alcoholism is a pathological behavioural syndrome, characterised by comp- sive alcohol use, craving and relapses, even recurring after many years of abstinence. It is suggested that chronic alcohol abuse leads to persistent changes within several neurochemical pathways in the brain and furthermore that an imprinted drug and addiction memory may scarcely be extinguished. Hence, the question arises as to whether there ought to be a reasonable hope that pharmacological drugs will be developed that interfere with an addiction memory, and as a result, finally lead to a cure? In this book, leading preclinical and clinical experts in the field of alcohol relapse prevention strive to furnish an answer to this question. None of the researchers or clinicians believes in a magic bullet that will be of help to all alcoholic patients in overcoming this disease. However, there is now convi- ing evidence demonstrating that specific subpopulations of alcoholic patients experience satisfactory benefit from currently available treatments. Today we have two medications for relapse prevention on the market - acamprosate and naltrexone. Although, currently, only a minority of alcoholic patients benefit from these medications, the approval of these compounds may be considered a hallmark in the field of psychopharmacology, even comparable to the era when the first antidepressant compounds were introduced. In recent years we have been witnessing an enormous growth in the science and knowledge regarding the field of relapse prevention.
Klappentext zu „Drugs for Relapse Prevention of Alcoholism “
Alcoholism is a pathological behavioural syndrome, characterised by comp- sive alcohol use, craving and relapses, even recurring after many years of abstinence. It is suggested that chronic alcohol abuse leads to persistent changes within several neurochemical pathways in the brain and furthermore that an imprinted drug and addiction memory may scarcely be extinguished. Hence, the question arises as to whether there ought to be a reasonable hope that pharmacological drugs will be developed that interfere with an addiction memory, and as a result, finally lead to a cure? In this book, leading preclinical and clinical experts in the field of alcohol relapse prevention strive to furnish an answer to this question. None of the researchers or clinicians believes in a magic bullet that will be of help to all alcoholic patients in overcoming this disease. However, there is now convi- ing evidence demonstrating that specific subpopulations of alcoholic patients experience satisfactory benefit from currently available treatments. Today we have two medications for relapse prevention on the market - acamprosate and naltrexone. Although, currently, only a minority of alcoholic patients benefit from these medications, the approval of these compounds may be considered a hallmark in the field of psychopharmacology, even comparable to the era when the first antidepressant compounds were introduced. In recent years we have been witnessing an enormous growth in the science and knowledge regarding the field of relapse prevention.
Inhaltsverzeichnis zu „Drugs for Relapse Prevention of Alcoholism “
From the contents:History of prevention of relapse- How to measure relapse in animals
- How to measure relapse in humans
- Disulfiram (Antabus): the first medication to stop drinking
- Naltrexone: preclinical and clinical data
- Acamprosate: preclinical and clinical data
- Serotonergic compounds: preclinical and clinical data
- Opioidergic compounds: preclinical and clinical data
- Glutamatergic compounds: preclinical and clinical data
- Dopaminergic compounds: preclinical and clinical data
- Baclofen: preclinical and clinical data
- Cholinergic compounds: preclinical and clinical data
- Cannabinoid receptor antagonists: a perspective
- Neuropeptide Y antagonists: a perspective
- Glutamatergic compounds: preclinical data
- The future of relapse prevention
Bibliographische Angaben
- 2005, 2005, 244 Seiten, Maße: 17,2 x 24,1 cm, Gebunden, Englisch
- Herausgegeben:Spanagel, Rainer; Mann, Karl F.
- Herausgegeben: Karl Mann, Rainer Spanagel
- Verlag: Springer
- ISBN-10: 3764302143
- ISBN-13: 9783764302146
- Erscheinungsdatum: 15.12.2004
Sprache:
Englisch
Rezension zu „Drugs for Relapse Prevention of Alcoholism “
"The book was a delight to read and the editors must be congratulated on bringing together a diverse group of experts to describe both the pre-clinical and clinical aspects of this topical issue. (...) This book will more than fulfil the requirements of a clinician looking for information about the underlying neurobiology of pharmacotherapy."(Addiction)
Kommentar zu "Drugs for Relapse Prevention of Alcoholism"
0 Gebrauchte Artikel zu „Drugs for Relapse Prevention of Alcoholism“
Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
---|
Schreiben Sie einen Kommentar zu "Drugs for Relapse Prevention of Alcoholism".
Kommentar verfassen